Myriad Women's Health

Myriad Women's Health is the women's health genetic testing business within Myriad Genetics, focused on reproductive health and hereditary cancer risk assessment. Its commercial product portfolio includes the Foresight Carrier Screen, Prequel Prenatal Screen, MyRisk Hereditary Cancer Test with RiskScore, and SneakPeek Early Gender DNA Test. The business serves obstetric, gynecology, health system, and consumer channels with testing, clinical support, patient education, and integrated service offerings. Myriad Women's Health was built in part through Myriad Genetics' acquisition of Counsyl in 2018 and was later expanded by the 2022 acquisition of Gateway Genomics and SneakPeek. It is a commercial diagnostics business rather than a therapeutics developer, with revenue generated from marketed genetic tests and related services.